Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.064 AUD | +4.92% | +6.67% | -9.86% |
Apr. 04 | Noxopharm Receives AU$100,000 to Progress Brain Cancer Drug | MT |
Feb. 27 | Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive | MT |
Sales 2022 | 5.43M 3.55M | Sales 2023 | 6.01M 3.93M | Capitalization | 12.57M 8.22M |
---|---|---|---|---|---|
Net income 2022 | -18M -11.78M | Net income 2023 | -15M -9.81M | EV / Sales 2022 | 7.95 x |
Net cash position 2022 | 13.85M 9.06M | Net cash position 2023 | 3.01M 1.97M | EV / Sales 2023 | 1.59 x |
P/E ratio 2022 |
-3.04
x | P/E ratio 2023 |
-0.83
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.79% |
1 day | +4.92% | ||
1 week | +6.67% | ||
Current month | -4.48% | ||
1 month | +4.92% | ||
3 months | -3.03% | ||
6 months | -33.33% | ||
Current year | -9.86% |
Managers | Title | Age | Since |
---|---|---|---|
Gisela Mautner
CEO | Chief Executive Officer | - | - |
Director of Finance/CFO | - | 19-02-28 | |
Olivier Laczka
CTO | Chief Tech/Sci/R&D Officer | - | 19-10-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Bart
CHM | Chairman | 69 | 20-05-07 |
Peter Marks
BRD | Director/Board Member | 68 | 16-03-14 |
Boris Patkin
BRD | Director/Board Member | - | 20-03-25 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 0.064 | +4.92% | 59 631 |
24-04-22 | 0.061 | +1.67% | 15,505 |
24-04-19 | 0.06 | -3.23% | 215,468 |
24-04-18 | 0.062 | +3.33% | 12,401 |
24-04-17 | 0.06 | -5.51% | 486,889 |
Delayed Quote Australian S.E., April 25, 2024 at 11:37 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-9.86% | 11.6M | |
-4.66% | 87.53B | |
+2.63% | 40.42B | |
-21.76% | 29.48B | |
+56.27% | 25.43B | |
-14.78% | 15.59B | |
-18.49% | 11.49B | |
-15.61% | 11.1B | |
-44.02% | 11.3B | |
+4.87% | 8.75B |
- Stock Market
- Equities
- NOX Stock